Linda Avey is a General Partner at Humain Ventures and co-founder of 23andMe and Precisely, demonstrating leadership in biotechnology entrepreneurship. She serves on the Board of Fellows at Stanford Medicine and directs the Human Immunome Project, reflecting her expertise in medical research. Additionally, Avey advises the Autism Impact Fund and biotech companies Giant and Colossal Bio, underscoring her role in advancing health technology and immunology innovation.

‌